LEADER 02487nam 2200577 a 450 001 9911004765403321 005 20200520144314.0 010 $a1-62198-140-1 010 $a1-84973-341-4 035 $a(CKB)2670000000130809 035 $a(EBL)1185422 035 $a(OCoLC)798795445 035 $a(SSID)ssj0000667216 035 $a(PQKBManifestationID)12310063 035 $a(PQKBTitleCode)TC0000667216 035 $a(PQKBWorkID)10674434 035 $a(PQKB)11107576 035 $a(MiAaPQ)EBC1185422 035 $a(PPN)198476175 035 $a(MiAaPQ)EBC7424635 035 $a(Au-PeEL)EBL7424635 035 $a(EXLCZ)992670000000130809 100 $a20121212d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDrug design strategies $equantitative approaches /$fedited by David J. Livingstone, Andrew M. Davis 205 $a1st ed. 210 $aCambridge $cRSC Pub.$d2012 215 $a1 online resource (517 p.) 225 1 $aRSC drug discovery series,$x2041-3203 ;$vno. 13 300 $aDescription based upon print version of record. 311 $a1-84973-166-7 320 $aIncludes bibliographical references and index. 327 $ai-iv; v-vi; vii-xviii; 1-34; 35-59; 60-87; 88-107; 108-163; 164-191; 192-219; 267-278; 220-241; 242-266; 279-311; 312-344; 345-366; 367-396; 397-439; 440-457; 458-478; 479-498 330 $aThis book brings together drug design practitioners, all leaders in their field, who are actively advancing the field of quantitative methods to guide drug discovery, from structure-based design to empirical statistical models - from rule-based approaches to toxicology to the fields of bioinformatics and systems biology. The aim of the book is to show how various facets of the drug discovery process can be addressed in a quantitative fashion (ie: numerical analysis to enable robust predictions to be made). Each chapter includes a brief review of the topic showing the historical development of 410 0$aRSC drug discovery series ;$v13. 606 $aDrugs$xDesign$xComputer simulation 615 0$aDrugs$xDesign$xComputer simulation. 676 $a615.19 701 $aLivingstone$b D$g(David)$0862758 701 $aDavis$b Andrew M$01822377 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9911004765403321 996 $aDrug design strategies$94388535 997 $aUNINA